31,381 Shares in Teladoc Health, Inc. (NYSE:TDOC) Purchased by Centiva Capital LP

Centiva Capital LP acquired a new position in shares of Teladoc Health, Inc. (NYSE:TDOC) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 31,381 shares of the health services provider’s stock, valued at approximately $288,000.

Other hedge funds have also added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Teladoc Health by 15.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,701,161 shares of the health services provider’s stock worth $15,617,000 after purchasing an additional 228,004 shares during the last quarter. Clearline Capital LP grew its holdings in Teladoc Health by 395.6% during the second quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider’s stock valued at $42,682,000 after purchasing an additional 3,483,665 shares during the period. The Manufacturers Life Insurance Company increased its position in Teladoc Health by 195.3% in the second quarter. The Manufacturers Life Insurance Company now owns 95,307 shares of the health services provider’s stock worth $932,000 after buying an additional 63,028 shares during the last quarter. Jennison Associates LLC bought a new stake in shares of Teladoc Health in the third quarter valued at $1,544,000. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Teladoc Health by 477.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 370,093 shares of the health services provider’s stock valued at $3,397,000 after buying an additional 305,961 shares during the last quarter. Institutional investors own 76.82% of the company’s stock.

Insider Buying and Selling at Teladoc Health

In other Teladoc Health news, Director Thomas Mckinley purchased 4,000 shares of Teladoc Health stock in a transaction that occurred on Thursday, September 12th. The shares were bought at an average price of $7.69 per share, for a total transaction of $30,760.00. Following the acquisition, the director now directly owns 39,077 shares in the company, valued at approximately $300,502.13. This trade represents a 11.40 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Carlos Nueno sold 2,389 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $11.93, for a total value of $28,500.77. Following the completion of the sale, the insider now owns 2,890 shares of the company’s stock, valued at approximately $34,477.70. This trade represents a 45.25 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.95% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on TDOC. Deutsche Bank Aktiengesellschaft boosted their price objective on Teladoc Health from $10.00 to $12.00 and gave the company a “hold” rating in a research note on Friday, November 1st. Piper Sandler restated an “overweight” rating and set a $13.00 price target (up from $11.00) on shares of Teladoc Health in a research note on Wednesday, December 4th. Jefferies Financial Group lifted their price objective on shares of Teladoc Health from $8.00 to $10.00 and gave the company a “hold” rating in a research note on Tuesday, September 17th. JPMorgan Chase & Co. lowered their target price on shares of Teladoc Health from $16.00 to $9.00 and set a “neutral” rating on the stock in a report on Monday, August 26th. Finally, Evercore ISI increased their price target on shares of Teladoc Health from $8.00 to $9.00 and gave the stock an “in-line” rating in a report on Tuesday, October 8th. Fourteen analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $12.24.

Teladoc Health Price Performance

Shares of NYSE:TDOC opened at $10.61 on Wednesday. The company has a quick ratio of 1.69, a current ratio of 1.73 and a debt-to-equity ratio of 0.66. The stock has a market cap of $1.83 billion, a PE ratio of -1.84 and a beta of 0.97. The company’s fifty day moving average is $9.70 and its 200 day moving average is $9.17. Teladoc Health, Inc. has a 52 week low of $6.76 and a 52 week high of $22.54.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, October 30th. The health services provider reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.10. The firm had revenue of $640.51 million for the quarter, compared to the consensus estimate of $630.50 million. Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. Research analysts anticipate that Teladoc Health, Inc. will post -1.16 earnings per share for the current year.

Teladoc Health Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.